PT - JOURNAL ARTICLE AU - CLOVIS O. DA FONSECA AU - RAPHAEL M. TEIXEIRA AU - JÚLIO CESAR T. SILVA AU - JULIANA DE SALDANHA DA GAMA FISCHER AU - OSÓRIO C. MEIRELLES AU - JOSE ALBERTO LANDEIRO AU - THEREZA QUIRICO-SANTOS TI - Long-term Outcome in Patients with Recurrent Malignant Glioma Treated with Perillyl Alcohol Inhalation DP - 2013 Dec 01 TA - Anticancer Research PG - 5625--5631 VI - 33 IP - 12 4099 - http://ar.iiarjournals.org/content/33/12/5625.short 4100 - http://ar.iiarjournals.org/content/33/12/5625.full SO - Anticancer Res2013 Dec 01; 33 AB - Aim: This retrospective study aimed to evaluate the long-term response and toxicity of recurrent malignant glioma patients to inhalation chemotherapy with perillyl alcohol (POH). Patients and Methods: The cohort included 117 men and 81 women with primary glioblastoma multiforme (GBM; n=154), grade III astrocytoma (AA; n=26) and anaplastic oligodendroglioma (AO; n=5). POH inhalation schedule 4-times daily started with 66.7 mg/dose; 266 mg/day and escalated up to 133.4 mg/dose; 533.6 mg/day. Clinical toxicity and overall survival following treatment were compared with tumor size, topography, extent of peritumoral edema and histological classification. Results: Adhesion to the protocol was high (>95%), POH (533.6 mg/daily) occasionally caused nose soreness but rarely nosebleed. Tumor size, peritumoral edema and the oligodendroglial component influenced response to treatment. Conclusion: After 4 years under exclusive POH treatment, 19% of patients still remain in clinical remission. Long-term POH inhalation chemotherapy is a safe and non-invasive strategy efficient for recurrent malignant glioma.